The roles of LSD1-mediated epigenetic modifications in maintaining the pluripotency of bladder cancer stem cells

Medical Hypotheses

Volumn 81, Issue 5, 2013, Pages 823-825

  Lan, Weihua ^a   Zhang, Dianzheng ^b   Jiang, Jun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEMETHYLASE; HISTONE H3; LYSINE SPECIFIC DEMETHYLASE 1; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER PROGNOSIS; CANCER STEM CELL; CANCER TISSUE; CELL RENEWAL; DEVELOPMENTAL GENE; DNA MODIFICATION; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; HISTONE METHYLATION; HUMAN; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; MOLECULAR IMPRINTING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION;

EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEMETHYLASES; HUMANS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; PLURIPOTENT STEM CELLS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84886782948     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.09.005     Document Type: Article

References (26)

1. Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol 2009, 27(3):289-293.
2. Besaratinia A., Tommasi S. Genotoxicity of tobacco smoke-derived aromatic amines and bladder cancer: current state of knowledge and future research directions. FASEB J 2013, 27(6):2090-2100.
3. Tran M.N., Goodwin Jinesh G., McConkey D.J., et al. Bladder cancer stem cells. Curr Stem Cell Res Ther 2010, 5(4):387-395.
4. Bryan R.T. Bladder cancer and cancer stem cells: basic science and implications for therapy. Sci World J 2011, 11:1187-1194.
5. Brandt W.D., Matsui W., Rosenberg J.E., et al. Urothelial carcinoma: stem cells on the edge. Cancer Metast Rev 2009, 28(3-4):291-304.
6. Chan K.S., Espinosa I., Chao M., et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009, 106(33):1Herston4016-14021.
7. He X., Marchionni L., Hansel D.E., et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 2009, 27(7):1487-1495.
8. Dalerba P., Dylla S.J., Park I.K., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007, 104(24):10158-10163.
9. Patrawala L., Calhoun T., Schneider-Broussard R., et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25(12):1696-1708.
10. Sheng X., Li Z., Wang D.L., et al. Isolation and enrichment of PC-3 prostate cancer stem-like cells using MACS and serum-free medium. Oncol Lett 2013, 5(3):787-792.
11. Singh B.N., Shankar S., Srivastava R.K. Cancer stem cells: biology, perspectives and therapeutic implications. Stem cells and human diseases 2012, 1-22. Springer, Dordrecht, Heidelberg, London, New York. R.K. Srivastava, S. Shankar (Eds.).
12. Thangappan R., Kurzrock E.A. Three clonal types of urothelium with different capacities for replication. Cell Prolif 2009, 42(6):770-779.
13. Yang Y.M., Chang J.W. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest 2008, 26(7):725-733.
14. Ning Z.F., Huang Y.J., Lin T.X., et al. Subpopulations of stem-like cells in side population cells from the human bladder transitional cell cancer cell line T24. J Int Med Res 2009, 37(3):621-630.
15. Ben-Porath I., Thomson M.W., Carey V.J., et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40(5):499-507.
16. Chan K.S., Volkmer J.P., Weissman I. Cancer stem cells in bladder cancer: a revisited and evolving concept. Curr Opin Urol 2010, 20(5):393-397.
17. Cheung P., Lau P. Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 2005, 19(3):563-573.
18. Bernstein B.E., Mikkelsen T.S., Xie X., et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125(2):315-326.
19. Shi Y., Lan F., Matson C., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119(7):941-953.
20. Adamo A., Sesé B., Boue S., et al. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat Cell Biol 2011, 13(6):652-659.
21. Sun G., Alzayady K., Stewart R., et al. Histone demethylase LSD1 regulates neural stem cell proliferation. Mol Cell Biol 2010, 30(8):1997-2005.
22. Wang J., Lu F., Ren Q., et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res 2011, 71(23):7238-7249.
23. Sprüssel A., Schulte J.H., Weber S., et al. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia 2012, 26(9):2039-2051.
24. Harris W.J., Huang X., Lynch J.T., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21(4):473-487.
25. Hayami S., Kelly J.D., Cho H.S., et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011, 128(3):574-586.
26. Kauffman E.C., Robinson B.D., Downes M.J., et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 2011, 50(12):931-944.